|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17((S3)): S43–S46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parise CA and Caggiano V: Breast cancer
survival defined by the ER/PR/HER2 subtypes and a surrogate
classification according to tumor grade and immunohistochemical
biomarkers. J Cancer Epidemiol. 2014:4692512014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narasimha AM, Kaulich M, Shapiro GS, Choi
YJ, Sicinski P and Dowdy SF: Cyclin D activates the Rb tumor
suppressor by mono-phosphorylation. Elife. 3:e028722014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foster DA, Yellen P, Xu L and Saqcena M:
Regulation of G1 cell cycle progression: Distinguishing the
restriction point from a nutrient-sensing cell growth
checkpoint(s). Genes Cancer. 11:1124–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clark AS, Karasic TB, DeMichele A, Vaughn
DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M and
O'Dwyer PJ: Palbociclib (PD0332991)-a selective and potent
cyclin-dependent kinase inhibitor: A review of pharmacodynamics and
clinical development. JAMA Oncol. 2:253–260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Corona SP and Generali D: Abemaciclib: A
CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast
cancer. Drug Des Devel Ther. 12:321–330. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Asghar US, Barr AR, Cutts R, Beaney M,
Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, et
al: Single-cell dynamics determines response to CDK4/6 inhibition
in triple-negative breast cancer. Clin Cancer Res. 23:5561–5572.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cretella D, Fumarola C, Bonelli M, Alfieri
R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D and
Petronini PG: Pre-treatment with the CDK4/6 inhibitor palbociclib
improves the efficacy of paclitaxel in TNBC cells. Sci Rep.
9:130142019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cretella D, Ravelli A, Fumarola C, La
Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali
D, Bonelli M and Petronini PG: The anti-tumor efficacy of CDK4/6
inhibition is enhanced by the combination with PI3K/AKT/mTOR
inhibitors through impairment of glucose metabolism in TNBC cells.
J Exp Clin Cancer Res. 37:722018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto T, Kanaya N, Somlo G and Chen S:
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib
and dual mTOR kinase inhibitor MLN0128 in pRb-expressing
ER-negative breast cancer. Breast Cancer Res Treat. 174:615–625.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Winter M, Nait Eldjoudi A, Guette C,
Hondermarck H, Bourette RP, Fovez Q, Laine W, Ghesquiere B,
Adriaenssens E, Kluza J and Le Bourhis X: Mitochondrial adaptation
decreases drug sensitivity of persistent triple negative breast
cancer cells surviving combinatory and sequential chemotherapy.
Neoplasia. 46:1009492023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koh SY, Moon JY, Unno T and Cho SK:
Baicalein suppresses stem cell-like characteristics in radio- and
chemoresistant MDA-MB-231 human breast cancer cells through
up-regulation of IFIT2. Nutrients. 11:6242019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Błaszczak E, Miziak P, Odrzywolski A,
Baran M, Gumbarewicz E and Stepulak A: Triple-negative breast
cancer progression and drug resistance in the context of
epithelial-mesenchymal transition. Cancers (Basel). 17:2282025.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takara K, Sakaeda T, Yagami T, Kobayashi
H, Ohmoto N, Horinouchi M, Nishiguchi K and Okumura K: Cytotoxic
effects of 27 anticancer drugs in HeLa and MDR1-overexpressing
derivative cell lines. Biol Pharm Bull. 25:771–778. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takara K, Kitada N, Yoshikawa E, Yamamoto
K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N and Yokoyama T:
Molecular changes to HeLa cells on continuous exposure to SN-38, an
active metabolite of irinotecan hydrochloride. Cancer Lett.
278:88–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakayama Y, Takara K, Minegaki T, Yamamoto
K, Omura T and Yano I: Induction of cross-resistance to ABCB1
substrates in venetoclax-resistant human leukemia HL60 cells.
Anticancer Res. 41:4239–4248. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lypova N, Lanceta L, Gibson A, Vega S,
Garza-Morales R, McMasters KM, Chesney J, Gomez-Gutierrez JG and
Imbert-Fernandez Y: Targeting palbociclib-resistant estrogen
receptor-positive breast cancer cells via oncolytic virotherapy.
Cancers (Basel). 11:6842019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lanceta L, Lypova N, O'Neill C, Li X,
Rouchka E, Chesney J and Imbert-Fernandez Y: Differential gene
expression analysis of palbociclib-resistant TNBC via RNA-seq.
Breast Cancer Res Treat. 186:677–686. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pesch AM, Hirsh NH, Michmerhuizen AR,
Jungles KM, Wilder-Romans K, Chandler BC, Liu M, Lerner LM, Nino
CA, Ward C, et al: RB expression confers sensitivity to CDK4/6
inhibitor-mediated radiosensitization across breast cancer
subtypes. JCI Insight. 7:e1544022022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tamura K, Mukai H, Naito Y, Yonemori K,
Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, et al:
Phase I study of palbociclib, a cyclin-dependent kinase 4/6
inhibitor, in Japanese patients. Cancer Sci. 107:755–763. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Armand J, Safonov A, Zhang M, Soni
RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, et al:
Sequential activation of E2F via Rb degradation and c-Myc drives
resistance to CDK4/6 inhibitors in breast cancer. Cell Rep.
42:1131982023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q,
Peng Y, Wang B, Chen Y, Xu S, et al: MYC induces CDK4/6 inhibitors
resistance by promoting pRB1 degradation. Nat Commun. 15:18712024.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandey K, Park N, Park KS, Hur J, Cho YB,
Kang M, An HJ, Kim S, Hwang S and Moon YW: Combined CDK2 and CDK4/6
inhibition overcomes palbociclib resistance in breast cancer by
enhancing senescence. Cancers (Basel). 12:35662020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai Z, Shi Q, Li Y, Jin L, Li S, Wong LL,
Wang J, Jiang X, Zhu M, Lin J, et al: LncRNA EILA promotes CDK4/6
inhibitor resistance in breast cancer by stabilizing cyclin E1
protein. Sci Adv. 9:eadi38212023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guarducci C, Bonechi M, Benelli M,
Biagioni C, Boccalini G, Romagnoli D, Verardo R, Schiff R, Osborne
CK, De Angelis C, et al: Cyclin E1 and Rb modulation as common
events at time of resistance to palbociclib in hormone
receptor-positive breast cancer. NPJ Breast Cancer. 4:382018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Gooijer MC, Zhang P, Thota N,
Mayayo-Peralta I, Buil LCM, Beijnen JH and van Tellingen O:
P-glycoprotein and breast cancer resistance protein restrict the
brain penetration of the CDK4/6 inhibitor palbociclib. Invest New
Drugs. 33:1012–1019. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu T, Chen Z, To KKW, Fang X, Wang F,
Cheng B and Fu L: Effect of abemaciclib (LY2835219) on enhancement
of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells
in vitro and in vivo. Biochem Pharmacol. 124:29–42. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martínez-Chávez A, Loos NHC, Lebre MC,
Tibben MM, Rosing H, Beijnen JH and Schinkel AH: ABCB1 and ABCG2
limit brain penetration and, together with CYP3A4, total plasma
exposure of abemaciclib and its active metabolites. Pharmacol Res.
178:1059542022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takara K, Sakaeda T and Okumura K: An
update on overcoming MDR1-mediated multidrug resistance in cancer
chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mohammad IS, He W and Yin L: Understanding
of human ATP binding cassette superfamily and novel multidrug
resistance modulators to overcome MDR. Biomed Pharmacother.
100:335–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ,
Gupta P, Shukla S, Ambudkar SV, Kong D and Chen ZS: Selonsertib
(GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in
ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 440–441.
82–93. 2019.
|
|
38
|
Modi A, Roy D, Sharma S, Vishnoi JR,
Pareek P, Elhence P, Sharma P and Purohit P: ABC transporters in
breast cancer: Their roles in multidrug resistance and beyond. J
Drug Target. 30:927–947. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fu H, Wu ZX, Lei ZN, Teng QX, Yang Y,
Ashby CR, Lei Y, Lian Y and Chen ZS: The resistance of cancer cells
to palbociclib, a cyclin-dependent kinase 4/6 inhibitor, is
mediated by the ABCB1 transporter. Front Pharmacol. 13:8616422022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Jiang J, Wu J, Bao X and Sanai N:
Physiologically based pharmacokinetic modeling of central nervous
system pharmacokinetics of CDK4/6 inhibitors to guide selection of
drug and dosing regimen for brain cancer treatment. Clin Pharmacol
Ther. 109:494–506. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Li Y, Hu C, Chen Y, Chen Z, Chen
ZS, Zhang JY and Fang S: CDK6-PI3K signaling axis is an efficient
target for attenuating ABCB1/P-gp mediated multi-drug resistance
(MDR) in cancer cells. Mol Cancer. 21:1032022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Bu X, Wang H, Zhu Y, Geng Y,
Nihira NT, Tan Y, Ci Y, Wu F, Dai X, et al: Cyclin D-CDK4 kinase
destabilizes PD-L1 via cullin 3-SPOP to control cancer immune
surveillance. Nature. 553:91–95. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shrestha M, Wang DY, Ben-David Y and
Zacksenhaus E: CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR
and PD-L1 expression in triple-negative breast cancer. Oncogenesis.
12:292023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Diehl JA: Cycling to cancer with cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gladden AB and Diehl JA: Cell cycle
progression without cyclin E/CDK2: Breaking down the walls of
dogma. Cancer Cell. 4:160–162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hurvitz SA, Martin M, Press MF, Chan D,
Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS,
Barriga S, et al: Potent cell-cycle inhibition and upregulation of
immune response with abemaciclib and anastrozole in neoMONARCH,
phase II neoadjuvant study in HR+/HER2−breast
cancer. Clin Cancer Res. 26:566–580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tolaney SM, de Azambuja E, Kalinsky K, Loi
S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, et al:
Sacituzumab govitecan plus pembrolizumab for advanced
triple-negative breast cancer. N Engl J Med. 394:354–366. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rugo HS, Cescon DW, Robson ME, Im SA,
Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk
S, et al: KEYLYNK-009: Pembrolizumab plus olaparib in locally
recurrent inoperable or metastatic triple-negative breast cancer
after clinical benefit from first-line pembrolizumab plus
chemotherapy. Clin Cancer Res. 32:883–893. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Malorni L, Piazza S, Ciani Y, Guarducci C,
Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A and Migliaccio
I: A gene expression signature of retinoblastoma loss-of-function
is a predictive biomarker of resistance to palbociclib in breast
cancer cell lines and is prognostic in patients with ER positive
early breast cancer. Oncotarget. 7:68012–68022. 2016. View Article : Google Scholar : PubMed/NCBI
|
